KR20210060501A - 6-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)니코틴아미드의 결정질 형태 - Google Patents

6-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)니코틴아미드의 결정질 형태 Download PDF

Info

Publication number
KR20210060501A
KR20210060501A KR1020217009903A KR20217009903A KR20210060501A KR 20210060501 A KR20210060501 A KR 20210060501A KR 1020217009903 A KR1020217009903 A KR 1020217009903A KR 20217009903 A KR20217009903 A KR 20217009903A KR 20210060501 A KR20210060501 A KR 20210060501A
Authority
KR
South Korea
Prior art keywords
type
shows
xrpd
crystalline form
nicotinamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217009903A
Other languages
English (en)
Korean (ko)
Inventor
샹양 천
줘펑 왕
리친 위
Original Assignee
베이징 이노케어 파마 테크 씨오., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이징 이노케어 파마 테크 씨오., 엘티디. filed Critical 베이징 이노케어 파마 테크 씨오., 엘티디.
Publication of KR20210060501A publication Critical patent/KR20210060501A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217009903A 2018-09-18 2019-09-18 6-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)니코틴아미드의 결정질 형태 Ceased KR20210060501A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732994P 2018-09-18 2018-09-18
US62/732,994 2018-09-18
PCT/CN2019/106433 WO2020057549A1 (en) 2018-09-18 2019-09-18 Crystalline forms of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide

Publications (1)

Publication Number Publication Date
KR20210060501A true KR20210060501A (ko) 2021-05-26

Family

ID=69888278

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217009903A Ceased KR20210060501A (ko) 2018-09-18 2019-09-18 6-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)니코틴아미드의 결정질 형태

Country Status (11)

Country Link
US (1) US11945792B2 (https=)
EP (1) EP3853217B1 (https=)
JP (1) JP2022501351A (https=)
KR (1) KR20210060501A (https=)
CN (2) CN112654607B (https=)
AU (1) AU2019341284B2 (https=)
CA (1) CA3111114A1 (https=)
ES (1) ES2951420T3 (https=)
MX (1) MX2021003064A (https=)
SG (1) SG11202102116XA (https=)
WO (1) WO2020057549A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115894440B (zh) * 2022-10-27 2024-10-22 都创(重庆)医药科技有限公司 奥布替尼化合物的晶型及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015028662A1 (en) 2013-08-30 2015-03-05 Consejo Superior De Investigaciones Cientificas (Csic) Compositions and methods for characterization and amelioration of rheumatoid arthritis
KR102272792B1 (ko) * 2013-09-30 2021-07-05 광저우 이노케어 파마 테크 씨오., 엘티디. Ｂｔｋ의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도
SG11201704808VA (en) * 2014-12-18 2017-07-28 Principia Biopharma Inc Treatment of pemphigus
US20180193274A1 (en) * 2014-12-24 2018-07-12 Principia Biopharma Inc. Compositions for ileo-jejunal drug delivery

Also Published As

Publication number Publication date
JP2022501351A (ja) 2022-01-06
CN116496247A (zh) 2023-07-28
AU2019341284A1 (en) 2021-04-15
CN112654607B (zh) 2023-01-13
CA3111114A1 (en) 2020-03-26
EP3853217A1 (en) 2021-07-28
WO2020057549A1 (en) 2020-03-26
EP3853217B1 (en) 2023-06-07
US11945792B2 (en) 2024-04-02
CN112654607A (zh) 2021-04-13
AU2019341284B2 (en) 2024-09-05
SG11202102116XA (en) 2021-04-29
ES2951420T3 (es) 2023-10-20
US20210188801A1 (en) 2021-06-24
MX2021003064A (es) 2021-05-27
EP3853217A4 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
JP6010154B2 (ja) Ｌ−オルニチンフェニルアセテートおよびその製造方法
ES2952770T3 (es) Formas de estado sólido de apalutamida
CN102985423A (zh) 嘌呤衍生物的结晶形式
US20180237438A1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
JP2012515210A (ja) ベンダムスチン遊離塩基の新規の形態
CN110291079A (zh) 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法
EA036874B1 (ru) Новые соли и полиморфы scy-078
US11945792B2 (en) Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide
US12492192B2 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
CN114181161A (zh) (2-((取代氧基)苯基)氨基)嘧啶-4-基)氨基苯甲酰衍生物及其制备方法与应用
ES3034394T3 (en) Salt of s-oxprenolol
JP2013184902A (ja) リファキシミン含有結晶
CN114026088A (zh) Jak2抑制剂的结晶形式
HK40048993B (en) Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl) nicotinamide
HK40048993A (en) Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl) nicotinamide
HK40096475A (zh) 6-(1-丙烯醯基哌啶-4-基)-2-(4-苯氧基苯基)尼克醯胺的晶型
US20170190742A1 (en) Composition of cyclic peptide compound, preparation method for same, and uses thereof
KR20230026384A (ko) 화합물의 결정 형태
TW202102510A (zh) 呋喃嘧啶化合物酸加成鹽之晶形及藥物組成物
EP4631496A1 (en) Solid dispersion, preparation method therefor, and use thereof
TWI876245B (zh) (2R, 3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新穎酸加成鹽及晶形
KR102815426B1 (ko) 스핑고신-1-인산 수용체 효능제의 약제학적으로 허용되는 염 및 이의 결정형
US11981624B2 (en) Crystalline polymorphs of Rigosertib Sodium
KR100948126B1 (ko) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CA3186319A1 (en) Crystal forms of crenolanib and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

V11 Administrative appeal requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V11-APL-PJ0201 (AS PROVIDED BY THE NATIONAL OFFICE)